BrettMaas.com

JPMorgan sees shares of Procter & Gamble rising 11% from current levels.

Roth’s $212 price target implies an additional upside of 32% for shares of Insmed, which have already rallied 160% in the last 12 months.

For the most part, Wall Street analysts maintained a hold-equivalent rating on Intel after supply constraints weighed on the company’s current-quarter outlook.

The three major averages jumped for a second consecutive session Thursday, with the Dow Industrials wiping out the week’s losses.

Celso Muñoz is among what Morningstar calls the “best-in-class” bond fund managers at Fidelity. Here is where he sees opportunity for income-oriented investors.

A few names have received three or more positive stock ratings since the end of 2025, suggesting the Street is becoming bullish on them.

The firm reiterated its buy ratings on IonQ and D-Wave Quantum, and upgraded its rating on another leading pure-play quantum stock.

The key question now is how much worse can it get for software when areas like semiconductors are pushing to new all-time highs.

When the credit card lender reports results Thursday, traders will be watching not just the numbers, but whether the company can extend an unusual streak.

Founder Chip Wilson’s activism may be helpful — and he has plenty of motivation to see things turn around.